First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment

Biological Psychiatry

Volumn 41, Issue 8, 1997, Pages 857-864

  Nagaoka, Shigeyuki ^a,b   Iwamoto, Norihiko ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Juntendo University Hospital   (Japan)

Author keywords

Drug naive; First episode; Monoamine metabolites; Neuroleptic treatment; Plasma; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; DOPAMINE; FEMALE; HALOPERIDOL; HUMANS; MALE; NOREPINEPHRINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN;

EID: 0030935816     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00244-2     Document Type: Article

References (41)

1. Alfredsson G, Wiesel F (1990): Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 101:324-331.
2. Arai H, Kosaka K, Iizuka R (1984): Change of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43:388-393.
3. Bacopoulus NG, Hattox SE, Roth RH (1979): 3,4-Dihydroxy phenylacetic acid and homovanillic acid in rat plasma; possible indicators of central dopaminergic activity. Eur J Pharmacol 56:225-236.
4. Bird ED, Spokes EG, Iverson LL (1979a): Brain norepinephrine and dopamine in schizophrenia. Science 204:93-94.
5. Bowers MB Jr, Swigar ME, Jatlow PI, Goicoechea N (1984): Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45:248-251.
6. Bowers MB, Swigar ME, Jatlow PI, Hoffman FJ (1989): Plasma catecholamine metabolites and treatment response at neuroleptic steady state. Biol Psychiatry 25:734-738.
7. Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D (1990): Plasma norepinephrine in chronic schizophrenia. Am J Psychiatry 147:1467-1470.
8. Chang WH, Sheinin M, Burns RS, Linnolia M (1983): Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. Acta Pharmacol Toxicol 53:275-279.
9. Crow TJ, Bakar HF, Cross AJ, Joseph MH, Lofthouse R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS (1979): Monoamine mechanisms in chronic schizophrenia; Post-mortem neurochemical findings. Br J Psychiatry 134: 249-246.
10. Davidson M, Davis KL (1988): A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561-563.
11. Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, Dumount K, Apter S, Davis KL (1991): Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 48:910-913.
12. Davidson M, Kahn RS, Powchik P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL (1991): Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48:73-76.
13. Davila R, Manero E, Zumarraga M, Andia I, Schweitzer J, Friedhoff A (1988): Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:564-567.
14. Davis KL, Kann RS, Ko G, Davidson M (1991): Dopamine in schizophrenia; A review and reconceptualization. Am J Psychiatry 148:1474-1486.
15. Farley IJ, Price KS, McCullough E (1978): Norepinephrine in chronic paranoid schizophrenia; above-normal levels in limbic forebrain. Science 200:456-458.
16. Javaid JI, Sharma RP, Janicak PG, Davis JM (1990): Plasma HVA in psychiatric patients; Longitudinal studies. Psychopharmacol Bull 26:361-365.
17. Joseph MH, Baker HF, Johnstone EC, Crow TJ (1976): Determination of 3-methoxy-4-hydroxyphenylglycol conjugates in urine. Application to the study of central noradrenaline metabolism in unmedicated chronic schizophrenic patients. Psychopharmacology 51:47-51.
18. Kemali D, Del Vecchio M, Maj M (1982): Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry 17:711-717.
19. Kendler KS, Davis KL (1984): Acute and chronic effects of neuroleptic drugs on plasma and homovanillic acid in the rat. Psychiatry Res 13:51-58.
20. Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ (1988): Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Res 25:233-242.
21. Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB (1988): Plasma 3-methoxy-4-hydroxyphenylglycol change associated with clinical state and schizophrenic subtype. Arch Gen Psychiatry 45:842-846.
22. Konicki PE, Owen RR, Litman RE, Pickar D (1991): The acute effects of central-and-peripheral acting dopamine antagonists on plasma HVA in schizophrenic patients. Life Sci 48:1411-1416.
23. Kopin IJ, Bankiewicz KS, Harvey-White J (1988): Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment; validation in monkeys treated with MPTP. Neuropsychopharmacology 2:119-125.
24. Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983): Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73-75.
25. Kopin IJ (1978): Measuring turnover of neurotransmitters in human brain. In Lipton MA, Di Mascio A, Killam KF (eds), Psychopharmacology: a generation of progress. New York: Raven Press, pp 933-942.
26. Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T (1994): Plasma homovanillic acid levels in first-episode schizophrenia. Arch Gen Psychiatry 51:132-138.
27. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub S (1993): Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacology 8:97-109.
28. Maas JW, Contreras SA, Seleshi E, Bowden CL (1988): Dopamine metabolism and disposition in schizophrenic patients. Arch Gen Psychiatry 45:553-1559.
29. Maas JW, Hattox SE, Greene NM, Landis DH (1980): Estimates of dopamine and serotonin synthesis by the awake human brain. J Neurochem 34:1547.
30. Markianos M, Botsis A, Arvanitis Y (1992): Biogenic amine metabolites in plasma of drug-naive schizophrenic patients; Associations with symptomatology. Biol Psychiatry 32:288-292.
31. Overall J, Gorham DR (1992): The Brief Psychiatric Rating Scale. Psychol ep 10:799-812.
32. Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ (1990): Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Arch Gen Psychiatry 47:641-648.
33. Pickar D, Breier A, Kelsoe J (1988): Plasma homovanillic acid as an index of central dopaminergic activity; Studies in schizophrenia patients. Ann NY Acad Sci 537:339-346.
34. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A (1986): Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43:669-676.
35. Pickar D, Laborca R, Linnolia M, Roy A, Hommer D, Everett D, Paul SM (1984): Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954-957.
36. 14C DOPA in cerebrospinal fluid and blood plasma of humans. Brain Res 4:106-109.
37. Rizzo V, Melzideril G, Achilli G, Cellerino GP (1991): Determination of neurochemicals in biological fluids by using an automated high-performance liquid Chromatographic system with a coulometric array detector. J Chromatogr 536:229-236.
38. Scheinin M, Chang WH, Kirk KL, Linnolia M (1983): Simultaneous determination of 3-methoxy-4-hydroxy-phenylglycol, 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Anal Biochem 131: 246-253.
39. Sharma R, Javaid JI, Janicak P, Faull K, Comaty J, Davis JM (1989): Plasma and CSF HVA before and after pharmacological treatment. Psychiatry Res 28:97-104.
40. Sternberg DE, van Kammen DP, Lake CR, Ballenger JC, Marder SR, Bunney WE Jr (1981): The effect of pimozid on CSF norepinephrine in schizophrenia. Am J Psychiatry 138:1045-1051.
41. van Kammen DP, Peters J, Yao J, van Kammen WB, Neylan T, Shaw D, Linnoila M (1990): Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 47:161-168.